SITAGLIPTIN/METFORMIN MYLAN 50/850 sitagliptin (as hydrochloride monohydrate) 50 mg and metformin hydrochloride 850 mg tablet blister pack

Land: Ástralía

Tungumál: enska

Heimild: Department of Health (Therapeutic Goods Administration)

Virkt innihaldsefni:

sitagliptin hydrochloride monohydrate, Quantity: 56.688 mg; metformin hydrochloride, Quantity: 850 mg

Fáanlegur frá:

Maple Healthcare Pty Ltd

Lyfjaform:

Tablet, film coated

Samsetning:

Excipient Ingredients: microcrystalline cellulose; povidone; sodium fumarate; sodium stearyl phthalamate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red

Stjórnsýsluleið:

Oral

Einingar í pakka:

Blister pack of 56

Gerð lyfseðils:

(S4) Prescription Only Medicine

Ábendingar:

SITAGLIPTIN/METFORMIN MYLAN (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate., [see 5.1 PHARMACODYNAMIC PROPERTIES, Clinical trials and 4.2 DOSE AND METHOD OF ADMINISTRATION].

Vörulýsing:

Visual Identification: Oval-shaped, pink colour biconvex, film-coated tablets debossed with S476 on one side and plain on the other side.; Container Type: Blister Pack; Container Material: PVC/PVDC; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Leyfisstaða:

Registered

Leyfisdagur:

2023-04-05